CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Emtricitabine/tenofovir disoproxil fumarate

Last Updated: February 4, 2016
Result type: Reports
Project Number: SR0479-000
Product Line: Reimbursement Review

Generic Name: Emtricitabine/tenofovir disoproxil fumarate

Brand Name: Truvada

Manufacturer: Gilead Sciences Canada Inc.

Therapeutic Area: HIV-1 infection, pre-exposure prophylaxis

Indications: HIV-1 infection, pre-exposure prophylaxis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 24, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions